Are We Ready for More BTK Inhibitors in Chronic Lymphoblastic Leukemia? Experts Discuss the Latest Data

Did you know that noncovalent Bruton tyrosine kinase (BTK) inhibitors are a potential solution to overcome the challenge of covalent BTK inhibitor resistance in chronic lymphoblastic leukemia (CLL)?

Credit available for this activity expires: 8/24/2023

Earn Credit / Learning Objectives & Disclosures: https://www.medscape.org/viewarticle/979645?src=mkm_podcast_addon_979645